This page shows the latest pegfilgrastim news and features for those working in and with pharma, biotech and healthcare.
These savings derived mainly from trastuzumab and bevacizumab to treat a range of cancers, infliximab for autoimmune diseases, and pegfilgrastim to treat chemotherapy-related neutropenia, says the report.
Follows a three year wait since initial rejection in 2016. Sandoz, Novartis’ generics and biosimilar division, has finally won approval for its Neulasta biosimilar Ziextenzo (pegfilgrastim) following a three year wait. ... The study compared Sandoz’
The company is starting to face biosimilar competition for white blood cell stimulator Neulasta (pegfilgrastim) as well as generic encroachment on Sensipar (cinacalcet) for secondary hyperparathyroidism, which together accounted for around
Overall, Amgen posted a 2% rise in revenues to $5.78bn in the quarter, despite pressure on older drugs like while blood cell booster Neulasta (pegfilgrastim) which showed the first signs
The three biosimilars are: Mylan’s Hulio (adalimumab), a version of AbbVie’s big-selling Humira for the treatment of certain inflammatory and autoimmune disorders; and Accord Healthcare’s Pelgraz (pegfilgrastim) ... and ERA Consulting’s Udenyca
drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...